TwentyTwentyTweets
Tweets by 2020health-
Join 7,195 other subscribers
-
Recent Posts
Pages
Tag Archives: PPRS
Threats to Mankind from Drug Resistant Bacteria and Viruses
The risk of an end to the human race may sound like science fiction. However, there are only a small number of threats that could theoretically lead to the extinction of mankind. The four main concerns that most experts share … Continue reading
Posted in Business, David Cameron, Drugs, Global Health, GPs, International, Most Significant, NHS, Pharma, Public Health, Rare conditions, Research, Vaccination
Tagged 2020health, AIDS, amoxicillin, Antibacterial, antibiotics, antiviral, Augmentin, bacteria, bacterial susceptibility, beta-lactam, beta-lactamase, bureaucracy, carpenem, cephalosporin, Ebola, end of mankind, Gilead, hepatitis, Hospitals, Human, hygiene, isolation, monobactam, NICE, pathogen, penicillin, plague, PPRS, prescribing, prevention, Prime Minister, Pseudomonas, R & D, R&D, rabies, Research, Research and development, resistance, sofosbuvir, Sovaldi, vaccine, virus, WHO
Comments Off on Threats to Mankind from Drug Resistant Bacteria and Viruses
Medical advisory body “NICE” should not spend too much time valuing drugs.
The UK National Institute for Health and Care Excellence (“NICE”) is currently holding a public consultation over its proposals for evaluating drugs. Drugs that are approved by NICE automatically become available for doctors to prescribe under the NHS throughout England … Continue reading
Posted in Business, CCGs, Commissioning, Department of Health, Drugs, Elderly, equality, Genetics, GPs, Health and Wellbeing, Health Bill, Health reform, Inequality, Innovation, Jeremy Hunt, NHS, NHS reforms, Patients, Pharma, Policy, Public Health, Research, Technology, Uncategorized, Wellbeing
Tagged 2020health, Clinical Commissioning Group, Commissioning, Department of Health, dose, elderly, General practitioner, government, GP, GPs, health, Health Bill, innovation, Jeremy Hunt, medicine, Medicines and Healthcare products Regulatory Agency, MHRA, National Health Service, National Institute for Health and Care Excellence, NHS, NICE, Old age, patient, Patients, pharmaceutical, PPRS, pricing, Proportionate QALY, Public Health, QALY, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot: Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.
The UK Government and the pharmaceutical industry shared many objectives throughout the recent drug pricing negotiations. For example, there was always broad agreement that: The total future drug bill needed to be affordable in the context of other spending in … Continue reading
Posted in Andrew Lansley, Business, Cancer, Department of Health, Drugs, Innovation, Jeremy Hunt, NHS, Patients, Pharma, Research, Smoking ban
Tagged 2020health, Andrew Lansley, Department of Health, Drugs, government, innovation, Jeremy Hunt, National Health Service, NHS, NICE, parallel export, parallel imporrt, patient, Patient Access Scheme, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing, VBP
1 Comment
Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.
David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading
Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care
Tagged 2020health, block-buster, competition, David Cameron, demand, Department of Health, drug pricing system, Drugs, elderly, GP, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, parallel exports, parallel imports, patient, Patients, pharmaceutical, Philosophy and Economics, Politics, PPE, PPRS, pricing, quality of life, R&D, reference price, Research, value-based, value-based pricing, VBP
Leave a comment
Guest Blogspot: A wrong decision on UK drug pricing could seriously undermine all the good work that HM Treasury and the Department for Business, Innovation and Skills have done to encourage the UK pharmaceutical industry.
The recent local elections highlight the political dangers ahead. The current UK coalition government has lost popularity through decisions that do not all relate to austerity measures. Shortly after the General Election Andrew Lansley’s plans to increase the say of … Continue reading
Posted in Andrew Lansley, Business, Department of Health, Drugs, Election, Global Health, Health Bill, NHS, Patient choice, Patients, Pharma, Policy, Research, Technology
Tagged 2020health, Andrew Lansley, AstraZeneca, Department of Health, Drugs, GlaxoSmithKline, GSK, health, Health Bill, innovation, medicine, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
Political Mood Change over the NHS, Innovation and the Pharmaceutical Industry in 2011
As 2011 draws to a close now is a good time to reflect on the period since the last UK General Election in 2010. We must consider what we have done right, what we have done wrong and what remains … Continue reading
Posted in Business, David Cameron, Department of Health, Drugs, Election, Genetics, Health Bill, Health Team, Hospitals, Innovation, NHS, Pharma, Policy, Research
Tagged 2020health, David Cameron, Department of Health, Drugs, genetics, government, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, Pfizer, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
Parallel importing and exporting of pharmaceuticals severely limits the options in designing an effective UK drug pricing scheme.
A fundamental principle of the EU is the establishment of a single market where products can be freely imported and exported between member states. In the case of pharmaceuticals this ideal conflicts with the freedom of individual countries to fix … Continue reading
Posted in Business, competition, Department of Health, Drugs, Innovation, NHS, Pharma, Policy, Research
Tagged 2020health, competition, Department of Health, Drugs, German pricing, innovation, Lilly, medicine, National Health Service, NHS, NICE, Novartis, parallel exporting, parallel importing, parallel trade, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
1 Comment
Is it possible for NICE to be objective about pharmaceutical pricing?
Guest Blog: Barbara Arzymanow The Government appears to recognise the past shortcomings of NICE (National Institute for Health and Clinical Excellence) but no other organisation in the UK is appropriate to make expert recommendations on the value of individual drugs. … Continue reading
Posted in Andrew Lansley, Department of Health, Drugs, NHS, Pharma, Research
Tagged 2020health, Andrew lansley, Department of Health, Drugs, National Health Service, NHS, NICE, patient, pharmaceutical, PPRS, pricing, value-based pricing
1 Comment
Guest Blogspot – The UK Government’s Latest Thinking on the Value-Based Pricing of Medicines
The UK Government yesterday published its detailed response to the three-month public consultation concluded in March 2011 on value-based pharmaceutical pricing. The Government has emphasised that work on the proposals is still at an early stage. The mistake made with … Continue reading
Posted in Andrew Lansley, Business, Department of Health, Drugs, Employment, Finance, Innovation, NHS, Patients, Pharma, Policy, Research
Tagged 2020health, Alzheimer's Disease, Andrew Dillon, Andrew lansley, Department of Health, Drugs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, patient, patient access, Patients, Pfizer, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot- Dept. of Health Consultation on Drug Pricing: “A new value-based approach to the pricing of branded medicines”
The Department of Health deadline for public submissions on pharmaceutical pricing is this Thursday. Many pitfalls must be avoided if the Government’s proposals are to form the basis of a successful drug pricing policy. Some problems are not easy to … Continue reading
Posted in Andrew Lansley, Business, competition, Department of Health, Drugs, NHS, Pharma, Policy, Research, Uncategorized
Tagged 2020health, Andrew lansley, competition, David Jack, Department of Health, Drugs, health, innovation, innovative, medicine, National Health Service, NHS, parallel export, parallel import, patent box, pharmaceutical, PPRS, pricing, R&D, R&D tax credit, Research, unmet, unmet clinical need, unmet healthcare need, unmet medical need, value-based, value-based pricing, winner takes all
3 Comments
2020health's Blog 
You must be logged in to post a comment.